Peer-influenced content. Sources you trust. No registration required. This is HCN.

Pharmacy Practice NewsCOVID-19 Boosters Elicit Response Against Viral Variants

The new Moderna bivalent vaccine showed higher antibody development vs BA.4/BA.5 than the original version and also showed activity (although lower) against the new BQ1.1 strain. The Pfizer-BioNTech bivalent vaccine generated 3- to 5-fold higher antibody levels than the original vaccine against BA.4/.5 and 11-fold higher levels vs the newer variants.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form